Mirae Asset Global Investments Co. Ltd. Has $732,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 6.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 122,180 shares of the biotechnology company’s stock after buying an additional 7,220 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in BioCryst Pharmaceuticals were worth $732,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in shares of BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares during the period. Teacher Retirement System of Texas grew its position in shares of BioCryst Pharmaceuticals by 4.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 2,519 shares during the period. Fifth Third Bancorp grew its position in shares of BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,500 shares during the period. Teza Capital Management LLC grew its position in shares of BioCryst Pharmaceuticals by 12.8% in the 3rd quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 4,180 shares during the period. Finally, Great Valley Advisor Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 34.7% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 4,200 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $13.83.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $4.21 on Thursday. The stock has a market capitalization of $867.89 million, a price-to-earnings ratio of -3.57 and a beta of 1.90. The stock’s 50 day moving average price is $5.16 and its two-hundred day moving average price is $5.56. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.18 and a 52 week high of $9.06.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.68 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.